A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis | Zendy

GuiQi Zhu | Zendy; Keqing Shi | Zendy; Guiqian Huang | Zendy; Liren Wang | Zendy; Yi-Qian Lin | Zendy; Martin Braddock | Zendy; Yongping Chen | Zendy; Mengtao Zhou | Zendy; MingHua Zheng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis

Author(s) -

GuiQi Zhu,

Keqing Shi,

Guiqian Huang,

Liren Wang,

Yi-Qian Lin,

Martin Braddock,

Yongping Chen,

Mengtao Zhou,

MingHua Zheng

Publication year - 2015

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.5610

Subject(s) - medicine , ursodeoxycholic acid , gastroenterology , hazard ratio , adverse effect , liver transplantation , regimen , primary sclerosing cholangitis , bilirubin , randomized controlled trial , odds ratio , transplantation , confidence interval , disease

Therapies for treatment of patients with primary sclerosing cholangitis (PSC) include administration of ursodeoxycholic acid (UDCA) alone, or combination with metronidazole (MTZ) or mycophenolate mofetil (MMF), respectively. However, the optimum regimen still remains inconclusive. We aimed to compare interventions in terms of patient mortality or liver transplantation (MOLT), progression of liver histological stage (POLHS), serum bilirubin, alkaline phosphatase (ALP) levels and adverse events (AE).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research